Rankings / Hormones & Endocrine
Cabergoline
Hormones & Endocrine · Dopamine D2 agonist
Tier B
Bottom line
Read Off Label grades Cabergoline as B (6.8/10) based on strong evidence, strong benefit magnitude, and a med-risk safety profile.
Valvulopathy risk is real and dose-dependent — chronic Parkinson's-level dosing (3+ mg/day) is clearly associated; prolactinoma doses less certain.
Typical use: 0. — Rx.
What this is
Valvulopathy risk is real and dose-dependent — chronic Parkinson's-level dosing (3+ mg/day) is clearly associated; prolactinoma doses less certain. Biohacker microdoses (0.25 mg weekly) are much lower than valvulopathy-risk dosing but long-term safety data in that population doesn't exist. Echo monitoring advised for chronic users.
Mechanism
Ergot-derived long-acting D2 dopamine receptor agonist; suppresses prolactin; used medically for hyperprolactinemia, prolactinoma, Parkinson's; off-label for post-orgasmic refractory reduction
Dose & route
0.25-0.5 mg once weekly (low-dose biohacker); 0.25-1 mg 2x/week (hyperprolactinemia)
Citations
- https://pubmed.ncbi.nlm.nih.gov/17182987/
- https://pubmed.ncbi.nlm.nih.gov/12677018/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3195418/
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Cabergoline work?
- Read Off Label rates the evidence for Cabergoline as Strong and the benefit magnitude as strong, producing an overall grade of B (6.8/10). Valvulopathy risk is real and dose-dependent — chronic Parkinson's-level dosing (3+ mg/day) is clearly associated; prolactinoma doses less certain.
- Is Cabergoline safe?
- Cabergoline has a med risk profile in published human data. Legal status: Rx (Dostinex). This is not medical advice — see the disclaimer.
- What is the typical dose for Cabergoline?
- 0.25-0.5 mg once weekly (low-dose biohacker); 0.25-1 mg 2x/week (hyperprolactinemia)
- How does Cabergoline work?
- Ergot-derived long-acting D2 dopamine receptor agonist; suppresses prolactin; used medically for hyperprolactinemia, prolactinoma, Parkinson's; off-label for post-orgasmic refractory reduction
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.